NeoGenomics Inc. (NEO)
NASDAQ: NEOHealth CarePrecision InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NEO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.05B
- Forward P/E
- 47.10
- EPS (TTM)
- -$0.38
- Dividend yield
- None
- 52-week range
- 7.07 – 20.15
- Day range
- 15.88 – 16.64
- Volume / Avg
- 3.19M / 2.36M
- Beta
- —
- Shares outstanding
- 128.48M
- Next earnings
- Oct 27, 2026
52-week range
NEO stock today
On Oct 7, NEO ended the session at $15.97, shedding $0.535 (3.24%), versus the S&P 500's 0.22% decline. At this level, NEO sits in the middle of its 52-week range of $7.07 to $20.15: 20.7% below the high, set on Oct 6, 2026 and 125.9% above the low. NEO is up 35.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 76.9%.
NeoGenomics has posted a net loss over the last twelve months (EPS of -$0.38), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of -$0.01.
Summary generated from market data by MetaCap's automated system. Methodology
About NeoGenomics
Company profileNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
- Sector
- Health Care
- Industry
- Precision Instruments
- CEO
- Mr. Anthony P. Zook
- Headquarters
- Fort Myers, FL
- Employees
- 2,500
- Website
- neogenomics.com
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$21.55+34.94%
- Strong buy 2
- Buy 7
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $-0.01
NEO news
All NEO news- Stryker, Neogenomics Announce CEO Transitions; Both Stocks DiveInvestor's Business DailyNEO, SYK
- Why Women-Run Companies Deserve a Place in Your PortfolioNasdaqBMY, TGT, ROST, HALO
- Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADLNasdaqBLSM, CADL, NEO, ORMP
- Noteworthy ETF Outflows: FBT, ONC, HALO, NEONasdaqFBT, ONC, HALO, NEO
NeoGenomics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AIDX20/20 Biolabs Inc. | 0.3435 | -2.55% | $4.39M | vs NEO |
Indexes, lists and sector
NeoGenomics stock FAQ
What is NeoGenomics's stock price today?
NEO last traded at $15.97 as of Oct 7, 4:00 PM EDT, down 3.24% on the day. Prices are delayed at least 15 minutes.
When is NeoGenomics's next earnings date?
NeoGenomics is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $-0.01.
Who is NeoGenomics's CEO?
Mr. Anthony P. Zook is the chief executive officer of NeoGenomics Inc., which has about 2,500 employees.
What is the NEO 52-week high?
The 52-week high for NEO is $20.15 and the 52-week low is $7.07. The stock is currently 20.7% below its high.